Jarrell M A, Heintz N, Howard P, Collins C, Badger G, Belinson J, Nason F
Department of Obstetrics and Gynecology, Vermont Cancer Center, Burlington 05401.
Gynecol Oncol. 1992 Sep;46(3):361-6. doi: 10.1016/0090-8258(92)90233-9.
In this study, the hypothesis that DNA ploidy and the presence of HPV 16 and HPV 18 DNA affects survival of patients with squamous cell carcinoma of the cervix was tested. Archival paraffin blocks from biopsy and surgical specimens were obtained from 127 women diagnosed in 1977-1984. Determination of DNA ploidy was by flow cytometry and HPV 16 and HPV 18 DNA status by polymerase chain reaction with subsequent dot-blot hybridization. For each patient, age, stage, treatment modality, and 5-year survival were correlated with ploidy and HPV status. HPV 16 DNA was present in 53% of the tumors. HPV 18 was not detected in this population. HPV 16 DNA was found twice as often in Stages IB and IIA than in advanced-stage disease (III and IV). These advanced-stage tumors were more commonly aneuploid. Neither HPV status nor DNA ploidy were predictive of survival for any stage of disease or therapeutic modality.
在本研究中,对DNA倍性以及HPV 16和HPV 18 DNA的存在是否影响子宫颈鳞状细胞癌患者生存率这一假说进行了检验。从1977年至1984年确诊的127名女性的活检及手术标本中获取存档石蜡块。通过流式细胞术测定DNA倍性,通过聚合酶链反应及随后的点杂交测定HPV 16和HPV 18 DNA状态。对于每位患者,将年龄、分期、治疗方式及5年生存率与倍性和HPV状态进行关联分析。53%的肿瘤中存在HPV 16 DNA。该人群中未检测到HPV 18。在IB期和IIA期肿瘤中发现HPV 16 DNA的频率是晚期疾病(III期和IV期)的两倍。这些晚期肿瘤更常见为非整倍体。HPV状态和DNA倍性均不能预测任何疾病分期或治疗方式患者的生存率。